Clinical trial · Interventional
Quantitative MRI in Assessing Disease in Patients With Brain Tumors
Quantitative High-Field Magnetic Resonance Imaging (MRI) for Assessing Brain Metastases
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Change in PI and funding
Summary
Brief summary (as posted)
This pilot clinical trial studies quantitative magnetic resonance imaging (MRI) at 3 Tesla in assessing disease in patients with tumors that have spread to the brain (brain metastases). In addition to routine care brain imaging of the brain, this study will include advanced multiparametric MRI sequences to measure vascular, cellular, and molecular properties of the tumor. Performing extra scans during MRI provides more information about the metastases and may better predict treatment response.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Tumors Metastatic to Brain | Brain Neoplasm | PROBABILISTIC | 0.70 |
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| chemical exchange saturation transfer magnetic resonance imaging | Procedure | — | UNRESOLVED |
| diffusion-weighted magnetic resonance imaging | Procedure | — | UNRESOLVED |
| dynamic contrast-enhanced magnetic resonance imaging | Procedure | — | UNRESOLVED |
| dynamic susceptibility contrast-enhanced magnetic resonance imaging | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Diagnostic (hybrid MRI)
- description
- Patients undergo hybrid 3 Tesla MRI examination that includes standard MRI sequences, DW-MRI, CEST, and combined DCE-MRI/DSC-MRI at baseline.
- interventionNames
- Procedure: diffusion-weighted magnetic resonance imaging
- Procedure: chemical exchange saturation transfer magnetic resonance imaging
- Procedure: dynamic contrast-enhanced magnetic resonance imaging
- Procedure: dynamic susceptibility contrast-enhanced magnetic resonance imaging
Primary outcomes (1)
- measure
- Volume transfer constant (Ktrans), as measured by DCE-MRI
- timeFrame
- Baseline
- description
- The ability of pre-treatment estimates of Ktrans to predict objective tumor response by Response Evaluation Criteria in Solid Tumors or Macdonald criteria after therapy will be assessed using the proportional odds model.
Secondary outcomes (7)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients must sign an Institutional Review Board (IRB)-approved informed consent document * Patients must have been diagnosed with one of the following: * Primary brain tumor (glioma, GBM etc); or * Up to 10 brain metastases * Patients must have been diagnosed with 1-4 brain metastases * At least one of the brain metastases must measure 5 mm (or more) in short axis diameter in the axial plane * Patients must be scheduled to undergo standard brain cancer interventions: * Chemotherapy or targeted antiangiogenic therapy, in the case of primary brain tumor; or * Stereotaxic radiotherapy (SRS) or whole brain radiotherapy (WBRT), in the case of brain metastases. * Patients must be scheduled to receive a 3-Tesla (3T) MRI exam as part of their standard of care (this exam will be modified to also include pulse sequences with are for research only) Exclusion Criteria: * Patients who have received previous treatment (chemotherapy or radiotherapy) for any brain tumor (primary or metastatic). * Patients who are scheduled to receive a 1.5T MRI exam * Patients incapable of giving informed written consent, due to mental disability, altered mental status, confusion, cognitive impairment, or psychiatric disorders. * Patients scoring 14.5 or lower on the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC) questionnaire will not be allowed on the study
References
Publications (0)
Data not yet available